FERRAU', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 3.709
EU - Europa 2.671
AS - Asia 2.537
SA - Sud America 899
AF - Africa 63
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AN - Antartide 1
Totale 9.884
Nazione #
US - Stati Uniti d'America 3.625
SG - Singapore 1.106
BR - Brasile 799
CN - Cina 747
IE - Irlanda 587
SE - Svezia 499
RU - Federazione Russa 409
IT - Italia 341
HK - Hong Kong 300
DE - Germania 195
PL - Polonia 170
GB - Regno Unito 151
VN - Vietnam 145
FI - Finlandia 80
FR - Francia 78
IN - India 56
CA - Canada 38
UA - Ucraina 37
AR - Argentina 34
MX - Messico 34
BE - Belgio 27
TR - Turchia 26
ZA - Sudafrica 26
ID - Indonesia 20
AT - Austria 18
BD - Bangladesh 18
EC - Ecuador 18
IQ - Iraq 16
UZ - Uzbekistan 16
CO - Colombia 14
JP - Giappone 14
CZ - Repubblica Ceca 13
ES - Italia 13
NL - Olanda 13
PK - Pakistan 11
LT - Lituania 10
MA - Marocco 9
VE - Venezuela 9
JO - Giordania 7
KE - Kenya 7
KG - Kirghizistan 7
PE - Perù 7
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
CI - Costa d'Avorio 5
CL - Cile 5
IL - Israele 5
NP - Nepal 5
TN - Tunisia 5
DZ - Algeria 4
PA - Panama 4
SA - Arabia Saudita 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CH - Svizzera 3
EE - Estonia 3
GE - Georgia 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
AM - Armenia 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
LB - Libano 2
LK - Sri Lanka 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
DK - Danimarca 1
GT - Guatemala 1
IR - Iran 1
JM - Giamaica 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.883
Città #
Dublin 586
Ashburn 540
Singapore 537
Chandler 492
Dallas 467
Beijing 327
Nyköping 303
Hong Kong 299
Warsaw 160
Messina 151
Jacksonville 124
Los Angeles 122
The Dalles 110
Munich 109
Princeton 102
Moscow 99
Medford 94
New York 80
Dearborn 77
Ann Arbor 76
Des Moines 71
Cambridge 65
São Paulo 58
Lancaster 54
Ho Chi Minh City 43
Shenyang 40
Redondo Beach 38
Buffalo 37
Jinan 34
Tianjin 31
Brooklyn 30
Boardman 29
Hyderabad 27
Rio de Janeiro 27
Brussels 26
Hanoi 26
Wilmington 26
Seattle 25
Belo Horizonte 24
Helsinki 24
Houston 24
London 24
Turku 24
Frankfurt am Main 22
Nanjing 22
Catania 20
Curitiba 19
Guangzhou 19
Johannesburg 17
San Mateo 17
Montreal 16
Tashkent 16
Jakarta 15
Santa Clara 15
Vienna 15
Zhengzhou 15
Atlanta 14
Council Bluffs 14
Denver 14
Dong Ket 14
Pune 14
Stockholm 14
Tokyo 14
Poplar 13
Ankara 12
Brasília 12
Bremen 12
Campinas 12
Düsseldorf 12
Hangzhou 12
Nanchang 12
Ningbo 11
Porto Alegre 11
Haikou 10
Lauterbourg 10
Nuremberg 10
Orem 10
Taizhou 10
Woodbridge 10
Boston 9
Mexico City 9
Milan 9
San Francisco 9
Toronto 9
Chennai 8
Chicago 8
Goiânia 8
Hebei 8
Manchester 8
Rome 8
Baghdad 7
Bexley 7
Bishkek 7
Brno 7
Changsha 7
Fairfield 7
Fortaleza 7
Franca 7
Fuzhou 7
Lima 7
Totale 6.330
Nome #
Aggressive pituitary adenomas: the dark side of the moon 190
Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas 181
Aggiornamento sulla chirurgia ipofisaria per via endoscopica: indicazioni, vantaggi e limiti 172
Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide 157
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. 154
Diabetes secondary to acromegaly: Physiopathology, clinical features and effects of treatment 151
Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities 146
Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies 135
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 134
Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden 133
Global epidemiology of acromegaly: A systematic review and meta-analysis 132
PRIMARY EMPTY SELLA IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK, REGARDLESS THE OCCURRENCE OF PITUITARY DYSFUNCTION 131
Increased prevalence of acromegaly in a highly polluted area. 130
Peptide receptor radionuclide therapy with 111IN-DTPA-Octreotide in a woman with Cabergoline-resistant giant prolactinoma 130
Course of Pregnancy in Cushing Disease under Different Management Approaches (No Treatment, Surgery, Gamma-Knife or Ketoconazole) 130
Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. 128
Effectiveness and safety of long-term pegvisomant administration in patients with acromegaly not controlled by other therapies: experience of an Italian center. 127
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly 126
P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study 125
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures 119
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study 117
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation 116
Comment to ‘glucocorticoid resistance syndrome caused by a novel nr3c1 point mutation’ by al argan et al. 114
Multidisciplinary management of pituitary apoplexy 111
Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients 111
Epidemiologia degli adenomi ipofisari nel nord-est della Sicilia 110
Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. 110
Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study 110
Effects of cyberknife radiotherapy treatment of pituitary adenomas 109
Course of pregnancies in women with Cushing's disease treated by gamma-knife 107
Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly 107
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide 105
Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing's disease: an Italian, multicenter study 104
Thyroid nodules in growth hormone replaced patients. 103
Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing[apos]s disease persistent after pituitary surgery 103
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 102
Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells 100
Adrenal Cushing Syndrome: Diagnosis and Management in a 10-Year-Old Boy with Carney Complex 99
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 99
Increased interleukin 22 circulating levels in patients with tumors involving the hypothalamic-pituitary region 97
First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy 97
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 96
Health-related quality of life in patients with Cushing's syndrome 96
Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. 95
Temozolomide-induced shrinkage of a pituitary carcinoma. 94
Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease. 93
Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis 93
An unusual case of idiopathic hyperprolactinemia 93
Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas 92
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 92
Pitfalls in the 2017 TNM Classification of Thyroid Carcinoma 89
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior 89
Increased serum brain natriuretic peptide levels are a major predictor of myocardial hypertrophy in acromegalic patients. 88
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 87
Endocrinologia & Malattie del Metabolismo 85
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. 83
Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma 83
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma 80
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 80
Genetic and epigenetic modulation of AHR pathway in GH-secreting pituitary tumors and effects on acromegaly clinical phenotype 79
Environmental Endocrinology and Endocrine Disruptors: Environmental Impact on the Hypothalamus–Pituitary Axis 79
The man with acromegaly who inspired the Shrek animated project. 79
Effects Of Epigenetic Changes In Gstp1 And Mgmt Gene On Clinicopathological Fatures Of Acromegaly Patients 78
Oral mucositis induced by treatment with soft gel formulation of levothyroxine 77
X-linked acrogigantism: a new condition of growth hormone excess. 77
Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy 74
Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. 74
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 74
GPR101 variants in acromegaly: results from a large series of patients. 72
The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease 72
Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors 72
Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case 71
Trabecular bone score, bone marrow fat and vertebral fractures in cushing syndrome 70
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis 70
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas 70
Landscape of familial isolated and young-onset pituitary adenomas: Prospective diagnosis in AIP mutation carriers 69
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report 69
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies 68
Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma 66
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients 66
How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild? 65
Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor 64
Unique clinical picture in patients with X-linked acrogigantism 64
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study 64
Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence 64
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 62
The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing's disease 61
Metabolic comorbidities in Cushing's syndrome 61
New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study 60
The Enhanced Proteasomal Degradation of AIP Mutant Proteins Is a Mechanism for AIP Deficiency in AIP mutation-Associated Pituitary Adenomas 60
Metabolic syndrome in cushing's syndrome patients 60
What we have to know about corticosteroids use during Sars-Cov-2 infection 60
Tertiary hypercortisolism due to occult Cushing's syndrome 59
Systemic comorbidities induce early vascular alterations in patients with active acromegaly. 58
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas 57
Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications 57
Somatic mutations in USP8 are frequent events in pituitary tumors causing Nelson's syndrome 56
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study 56
Sindromi ipercalcemiche 56
Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the THRB Gene Causing Resistance to Thyroid Hormone Syndrome 56
Totale 9.396
Categoria #
all - tutte 39.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.153


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021264 0 0 0 0 0 83 34 35 44 34 11 23
2021/2022662 1 69 12 30 18 10 27 23 10 97 120 245
2022/20231.733 164 180 78 136 115 158 36 91 691 14 43 27
2023/2024456 32 76 22 42 39 103 6 46 2 29 4 55
2024/20252.637 55 36 71 169 171 79 86 491 610 205 269 395
2025/20263.199 440 465 586 506 753 449 0 0 0 0 0 0
Totale 10.193